Rosiglitazone was noninferior to metformin plus sulfonylurea for CV events but increased risk for HF and fractures in type 2 diabetes

Lipscombe, Lorraine L.; Home, P. D.
October 2009
ACP Journal Club;10/20/2009, Vol. 151 Issue 4, p5
Academic Journal
The article discusses a study on the relation between rosiglitazone (RGZ) and metformin (MFN) or sulfonylurea (SFU) for cardiovascular (CV) results in type 2 diabetics. The results indicate that RGZ added to MFN or SFU was not less effective as compared to MFN and SFU for overall cardiovascular safety but also showed greater risks for heart failure and fractures.


Related Articles

  • Pioglitazone did not reduce macrovascular complications and increased HF in type 2 diabetes with macrovascular disease. Dormandy, J. A.; Charbonnel, B.; Eckland, D. J. // Evidence Based Medicine;Apr2006, Vol. 11 Issue 2, p47 

    The article focuses on the results of a study on the effectiveness of pioglitazone in reducing macrovascular complications and increased heart failure in type 2 diabetes with macrovascular disease. The drug reduced a composite end point of all cause mortality, non-fatal myocardial infarction and...

  • Commentary. Isley, William L. // Evidence Based Medicine;Apr2006, Vol. 11 Issue 2, p47 

    The article presents comments on a study on the use of pioglitazone in an effort to reduce macrovascular complications and increased heart failure in type 2 diabetes with macrovascular disease. Use of glitazones lead to fluid retention and weight gain. There were no clear evidence of...

  • EDITOR'S NOTE:. Walling, Anne D. // American Family Physician;4/15/2006, Vol. 73 Issue 8, p1459 

    Comments on a study on the general use of pioglitazone in patients with type 2 diabetes. Concerns about underestimation of heart failure and edema in study participants; Controversy surrounding the results.

  • Increased myocardial SERCA expression in early type 2 diabetes mellitus is insulin dependent: In vivo and in vitro data. Fredersdorf, Sabine; Thumann, Christian; Zimmermann, Wolfram H.; Vetter, Roland; Graf, Tobias; Luchner, Andreas; Riegger, Gnter A. J.; Schunkert, Heribert; Eschenhagen, Thomas; Weil, Joachim // Cardiovascular Diabetology;2012, Vol. 11 Issue 1, p57 

    Background: Calcium (Ca2+) handling proteins are known to play a pivotal role in the pathophysiology of cardiomyopathy. However little is known about early changes in the diabetic heart and the impact of insulin treatment (Ins). Methods: Zucker Diabetic Fatty rats treated with or without insulin...

  • Gender disparities in diabetes and coronary heart disease medication among patients with type 2 diabetes: results from the DIANA study. Kr„mer, Heike U.; Raum, Elke; Rter, Gernot; Sch”ttker, Ben; Rothenbacher, Dietrich; Rosemann, Thomas; Szecsenyi, Joachim; Brenner, Hermann // Cardiovascular Diabetology;2012, Vol. 11 Issue 1, p88 

    Background: Coronary heart disease (CHD) is one of the most common long-term complications in people with type 2 diabetes. We analyzed whether or not gender differences exist in diabetes and CHD medication among people with type 2 diabetes. Methods: The study was based on data from the baseline...

  • Addition of rosiglitazone to glucose-lowering therapy in people with type 2 diabetes increases adverse effects.  // Australian Journal of Pharmacy;Oct2009, Vol. 90 Issue 1073, p67 

    The article reports on the adverse effects when adding Rosiglitazone, an insulin sensitiser to glucose-lowering drugs which are given to people with type 2 diabetes. It notes that cardiovascular effects after adding rosiglitazone to either metformin or sulfonylurea, compared with the combination...

  • Reducing Cardiovascular Disease Risk in Patients with Type 2 Diabetes: A Message from the National Diabetes Education Program. Gavin III, James R.; Peterson, Kevin; Warren-Boulton, Elizabeth // American Family Physician;10/15/2003, Vol. 68 Issue 8, p1569 

    Deals with the efforts of the National Diabetes Education Program to increase patient awareness of the link between type 2 diabetes and heart disease. Scope of the problem; Rationale for risk reduction; Action plan to treat risk factors.

  • Development and validation of a risk score for hospitalization for heart failure in patients with Type 2 Diabetes Mellitus. Xilin Yang; Ma, Ronald C.; Wing-Yee So; Kong, Alice P.; Ko, Gary T.; Chun-Shun Ho; Lam, Christopher W.; Cockram, Clive S.; Tong, Peter C.; Chan, Juliana C. // Cardiovascular Diabetology;2008, Vol. 7, p1 

    Background: There are no risk scores available for predicting heart failure in Type 2 diabetes mellitus (T2DM). Based on the Hong Kong Diabetes Registry, this study aimed to develop and validate a risk score for predicting heart failure that needs hospitalisation in T2DM. Methods: 7067 Hong Kong...

  • The possible role of the ubiquitin proteasome system in the development of atherosclerosis in diabetes. Marfella, Raffaele; D'Amico, Michele; Di Filippo, Clara; Siniscalchi, Mario; Carlo sasso, Ferdinando; Ferraraccio, Franca; Rossi, Francesco; Paolisso, Giuseppe // Cardiovascular Diabetology;2007, Vol. 6, p35 

    We have reviewed the impact of the ubiquitin proteasome system (UPS) on atherosclerosis progression of diabetic patients. A puzzle of many pieces of evidence suggests that UPS, in addition to its role in the removal of damaged proteins, is involved in a number of biological processes including...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics